Advertisement

Current and Future Therapies for Osteoporosis

  • David M. Reid

Summary

Management of the fractures associated with osteoporosis consumes £942 million of resources annually in the United Kingdom and the burden of fractures is due to increase because of demographic change. Against this background new and innovative therapies are, or will shortly become, available. The current therapies most commonly used consist of the anti-resorptive agents hormone replacement therapy (HRT), bisphosphonates, the selective estrogen receptor modulators (SERMs) and calcium and vitamin D preparations. This chapter examines the issue of targeting therapy and debates the relative importance of these drugs in clinical practice. It examines new data showing that low dose HRT can be used effectively in the elderly and draws early conclusions on the likely impact of a new bisphosphonate, risedronate, compared with etidronate and alendronate, in the prevention and treatment of postmenopausal osteoporosis. Future possible developments, such as intravenous therapy and anabolic agents, such as parathyroid hormone are examined. Finally an individual approach to the choice of therapy is presented to stimulate debate as to a treatment schema.

Keywords

Bone Mineral Density Postmenopausal Woman Bone Mass Vertebral Fracture Hormone Replacement Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dolan P, Torgerson DJ.: The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 1998; 8: 611–17.PubMedCrossRefGoogle Scholar
  2. 2.
    Consensus Development Conference Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 94: 646–50.CrossRefGoogle Scholar
  3. 3.
    World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO Study Group. WHO technical report series 843, WHO, Geneva, 1994.Google Scholar
  4. 4.
    Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N.: The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137–41.PubMedCrossRefGoogle Scholar
  5. 5.
    Mazess RB, Barden HS.: T-scores differ among skeletal sites. Calcif Tissue Int 1999; 64 (S1): S104.Google Scholar
  6. 6.
    Royal College of Physicians. Clinical Guidelines for Strategies to Prevent and Treat Osteoporosis. London: Royal College of Physicians, 1999.Google Scholar
  7. 7.
    Eastell R. Drug therapy: Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338: 73646.Google Scholar
  8. 8.
    Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowitz MA.: Hip fracture and the use of estrogens in postmenopausal women: the Framingham Study. N Engl J Med 1987; 317: 1169–74.PubMedCrossRefGoogle Scholar
  9. 9.
    Maxim P, Ettinger B, Spitalny GM.: Fracture protection provided by long-term estrogen treatment. Osteoporos Int 1995; 5: 23–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR.: Estrogen replacement therapy and hip fractures. Ann Intern Med 1995; 122: 9–16.PubMedGoogle Scholar
  11. 11.
    Lufkin EG, Wahner HW, O’Fallon WM: Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1–9.PubMedGoogle Scholar
  12. 12.
    Komulainen MH, Kröger H, Tuppurainen T.: HRT and vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas 1998; 31: 45–54.PubMedCrossRefGoogle Scholar
  13. 13.
    Grodstein F, Stampfer MJ, Colditz GA.: Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769–75.PubMedCrossRefGoogle Scholar
  14. 14.
    Barrett-Connor E, Grady D.: Hormone replacement therapy, heart disease and other considerations. Annu Rev Public Health 1998; 19: 55–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Hulley S, Grady D, Bush T.: Randomized trial of estrogen plus progestin in the secondary prevention of coronary heart disease. JAMA 1998; 280: 605–13.PubMedCrossRefGoogle Scholar
  16. 16.
    Colditz GA, Hankinson SE, Hunter DJ.: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589–93.PubMedCrossRefGoogle Scholar
  17. 17.
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies and 52,705 women with breast cancer and 108,411 without breast cancer. Lancet 1997; 350: 1047–59.CrossRefGoogle Scholar
  18. 18.
    Torgerson DJ, Reid DM.: The pharmaco-economics of hormone replacement therapy. Pharmacoeconomics 1999; 16: 9–16.PubMedCrossRefGoogle Scholar
  19. 19.
    Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR: Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. JAMA 1996; 276: 1404–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Zhang Y, Kiel DP, Kreger BE.: Bone mineral density and the risk of breast cancer among postmenopausal women. N Engl J Med 1997; 336: 611–17.PubMedCrossRefGoogle Scholar
  21. 21.
    Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ.: The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329: 1141–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Lindsay R, Hart DM, Fogelman I: Bone mass after withdrawal of oestrogen replacement. Lancet 1981;i:370–1.Google Scholar
  23. 23.
    Recker R, Davies M, Dowd RM, Heaney RP.: The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. Ann Intern Med 1999; 130: 897–904.PubMedGoogle Scholar
  24. 24.
    Nieves JW, Komar L, Cosman F, Lindsay R.: Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am J Clin Nutr 1998; 67: 18–24.PubMedGoogle Scholar
  25. 25.
    Walsh BW, Kuller LH, Wild RA: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445–51.PubMedCrossRefGoogle Scholar
  26. 26.
    Delmas PD, Bjarnason NH, Mitlak BH.: Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Cummings SR, Eckert S, Krueger KA.: The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 1999; 281: 2189–97.PubMedCrossRefGoogle Scholar
  28. 28.
    Ettinger B, Black DM, Mitlak BH.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 1999; 282: 637–45.PubMedCrossRefGoogle Scholar
  29. 29.
    Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977–80.PubMedCrossRefGoogle Scholar
  30. 30.
    Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981–3.PubMedCrossRefGoogle Scholar
  31. 31.
    Perez-Gutthann S, Garcia-Rodriguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: a population based case control study. BMJ 1997; 314: 796–800.PubMedCrossRefGoogle Scholar
  32. 32.
    Francis RM. Oral bisphosphonates in the treatment of osteoporosis: a review. Current Therapeutic Research 1995; 56: 831–51.CrossRefGoogle Scholar
  33. 33.
    Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 332: 1265–71.CrossRefGoogle Scholar
  34. 34.
    Watts NB, Harris ST, Genant HK et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Harris ST, Watts NB, Jackson RD et al. Four-year study of intermittent cyclical etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993; 95: 557–67.PubMedCrossRefGoogle Scholar
  36. 36.
    Miller PD, Watts NB, Licata AA, Harris ST et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis: Am J Med 1997; 103: 468–76.PubMedGoogle Scholar
  37. 37.
    van Staa VP, Abenhaim L, Cooper C. Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheumatol 1998; 37: 87–94.PubMedCrossRefGoogle Scholar
  38. 38.
    Liberman UA, Weiss SR, Broil J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437–43.PubMedCrossRefGoogle Scholar
  39. 39.
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thomson ED. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 153541.Google Scholar
  40. 40.
    Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without fractures. JAMA 1998; 280: 2077–82.PubMedCrossRefGoogle Scholar
  41. 41.
    Pols HAP, Felsenberg D, Hamley DA et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999; 9: 461–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Karpf DB, Shapiro DR, Seeman E et al. Prevention of non-vertebral fractures by alendronate: a meta-analysis. JAMA 1997; 277: 1159–64.PubMedCrossRefGoogle Scholar
  43. 43.
    Harris ST, Watts NB, Genant HK et al. The effect of risedronate treatment on vertebral and non-vertebral fractures in women with post-menopausal osteoporosis: a double-blind randomized, placebo-controlled trial. JAMA 1999; 282: 1344–52.PubMedCrossRefGoogle Scholar
  44. 44.
    Mortensen L, Charles P, Bekker P, Diegennaro J, Johnston CC Jr. Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998; 83: 396–402.PubMedCrossRefGoogle Scholar
  45. 45.
    Reginster J-Y, Minne HW, Sorensen O, Hooper M, Roux C, Brandi ML et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 83–91.PubMedCrossRefGoogle Scholar
  46. 46.
    Miller P, Roux C, McClung M, Adami S, Eastell R, Pack S et al. Risedronate reduces hip fractures in patients with low femoral neck bone mineral density. Arthritis Rheum 1999; 42: S287.Google Scholar
  47. 47.
    Peretz A, Body JJ, Dumon JC et al. Cyclical pamidronate infusions in postmenopausal women. Maturitas 1997; 25: 69–75.CrossRefGoogle Scholar
  48. 48.
    Thiebaud D, Burckhardt P, Kriegbaum H et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997; 103: 298–307.PubMedCrossRefGoogle Scholar
  49. 49.
    De Groen PC, Lubbe DF, Hirsch LJ et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016–21.PubMedCrossRefGoogle Scholar
  50. 50.
    Bone H III, Adami S, Recker R et al. Alendronate 70 mg once weekly is therapeutically equivalent to alendronate 10 mg daily. 6th International Symposium on Clinical Disorders of Bone Mineral Metabolism, Venice, November 1999.Google Scholar
  51. 51.
    Watts NB, Becker P. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate. Bone 1999; 24: 65–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Rogers MJ, Frith JC, Luckman SP et al. Molecular mechanisms of action of bisphosphonates (review). Bone 1999; 24 (Suppl): 73S–79S.PubMedCrossRefGoogle Scholar
  53. 53.
    Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women. Am J Med 1995; 98: 331–5.PubMedCrossRefGoogle Scholar
  54. 54.
    Recker RR, Hinders, Davies KM et al. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 1996; 11: 1961–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Tilyard MW, Spears GFS, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992; 326: 357–62.PubMedCrossRefGoogle Scholar
  56. 56.
    Dawson-Hughes B, Harris S, Krall EA, Dallal GE. Effect of calcium and vitamin D on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337; 670–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Chapuy, MC, Arlot ME, Duboeuf F et al. Vitamin D and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637–42.PubMedCrossRefGoogle Scholar
  58. 58.
    Chapuy MC, Arlot ME, Demas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for 3 years on hip fractures in elderly women. BMJ 1994; 308: 1081–2.PubMedCrossRefGoogle Scholar
  59. 59.
    Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM. Vitamin D supplementation and fracture incidence in elderly persons. A randomized placebo-controlled clinical trial. Ann Intern Med 1996; 124: 400–6.PubMedGoogle Scholar
  60. 60.
    Heikinheimo RJ, Inkovaara JA, Harju EJ et al. Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 1992; 51: 105–10.PubMedCrossRefGoogle Scholar
  61. 61.
    Overgaard K, Hansen MA, Jensen S, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis. BMJ 1992; 305: 556–61.PubMedCrossRefGoogle Scholar
  62. 62.
    Kanis JA, McCloskey EV. Effect of calcitonin on vertebral and other fractures. Q J Med 1999; 92: 143–9.CrossRefGoogle Scholar
  63. 63.
    Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998; 104: 219–26.PubMedCrossRefGoogle Scholar
  64. 64.
    Bone HG, Greenspan SL, McKeever C et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/estrogen study group. J Clin Endocrinol Metab 2000; 85: 727–33.CrossRefGoogle Scholar
  65. 65.
    Pak CY, Sakhee K, Adams-Huet B, Piziak V, Paterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release fluoride: final report of a randomized controlled trial. Ann Intern Med 1995; 123: 401–8.PubMedGoogle Scholar
  66. 66.
    Meunier PJ, Sebert JL, Reginster JY et al. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVO Study. Osteoporos Int 1998; 8: 4–12.PubMedCrossRefGoogle Scholar
  67. 67.
    Lindsay R, Nieves J, Formica C et al. Randomised controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350: 550–5.PubMedCrossRefGoogle Scholar
  68. 68.
    Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive treatments are associated with change in bone density. J Bone Miner Res 1999; 14 (Suppl 1): 5508.Google Scholar
  69. 69.
    Black DM, Pearson J, Harris F, LaCroix A, Cummings SR. Predicting the effect of antiresorptive treatments on vertebral fractures: a meta-analysis. J Bone Miner Res 1999; 14 (Suppl 1): S137.CrossRefGoogle Scholar
  70. 70.
    Liggett NW, Reid DM. Osteoporosis and its management. Hospital Medicine 1999; 60: 238–42.PubMedGoogle Scholar
  71. 71.
    Close J, Ellis M, Hooper R, Glucksman E, Jackson S, Swift C. Prevention of falls in the elderly trial (PROFET): a randomised controlled trial. Lancet 1999; 353: 93–7.PubMedCrossRefGoogle Scholar
  72. 72.
    Lauritzen JB, Petersen MM, Lund B. Effect of external hip protectors on hip fractures. Lancet 1993; 341: 11–13.PubMedCrossRefGoogle Scholar
  73. 73.
    Ekman A, Mallmin H, Michaelsson K, Ljunghall S. External hip protectors to prevent osteoporotic hip fractures. Lancet 1997; 350: 563–4.PubMedCrossRefGoogle Scholar
  74. 74.
    Villar M, Hill P, Inskip H, Thompson P, Cooper C. Will elderly rest home residents wear hip protectors? Age Ageing 1998; 27: 195–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2002

Authors and Affiliations

  • David M. Reid

There are no affiliations available

Personalised recommendations